Investigational drug · Phase 2
GM103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GM103"
First trial start
2024
Feb 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GM103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Cancer
- Malignant Melanoma
- Colorectal Cancer
- Renal Cell Carcinoma
- Cervical Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Head and neck cancer · Cervical cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "GM103" as an intervention, largest first.
GeneMedicine Co., Ltd.Industry
NCT06265025 · 125 participants (planned) · Start Feb 20, 2024 · Primary completion May 30, 2025
Drug: GM103 (Part A); GM103 (Part B) and 1 more · For: Head and Neck Cancer; Malignant Melanoma; Colorectal Cancer and 3 more
Sites: Goyang-si, South Korea; Seoul, South Korea · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- First Report of Geosmithia morbida on English Walnut and its Paradox Rootstock in California.
Yaghmour MA, Nguyen TL, Roubtsova TV, et al. · Plant Dis 2014
Also in development for Head and Neck Cancer
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Buparlisib & PaclitaxelAN2025Phase 31 trial
Adlai Nortye Biopharma Co., Ltd. · Head and Neck Cancer
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- INCAGN02385Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- INCAGN02390Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- MCLA-129Phase 23 trials
Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.